Neurocognitive and emotional factors predict pain‐related healthcare utilization in children with sickle cell disease
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Steven J Hardy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Quality of Life, Anemia, Sickle Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, Doris Duke Charitable Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Youth with sickle cell disease (SCD) experience increased rates of neurocognitive and emotional difficulties. Cross‐sectional studies suggest neurocognitive and emotional functioning are associated with health outcomes in SCD. We investigated whether neurocognitive and emotional factors predicted future pain‐related healthcare utilization in children with SCD. Procedure Total 112 youth with SCD between ages 7 and 16 years reported sociodemographics and completed measures of neurocognitive functioning and emotional well‐being. The number of emergency department (ED) visits and hospitalizations for pain 1 and 3 years after enrollment were determined by chart review.
Results
The mean age of participants was 10.61 years (standard deviation = 2.91), with most being female ( n = 65; 58%). Eighty‐three (74%) participants had either HbSS or HbSβ 0 thalassemia. Regression analyses showed that attention significantly predicted ED visits and hospitalizations for pain at 1 and 3 years after enrollment (all p ‐values ≤ .017), such that poorer attention was associated with higher healthcare utilization. Lower emotional quality of life also predicted more ED visits for pain at 3 years ( b = −.009, p = .013) and hospitalizations for pain at 3 years ( b = −.008, p = .020).
Conclusions
Neurocognitive and emotional factors are associated with subsequent healthcare use in youth with SCD. Poor attentional control might limit implementation of strategies to distract from pain or could make disease self‐management behaviors more challenging. Results also highlight the potential impact of stress on pain onset, perception, and management. Clinicians should consider neurocognitive and emotional factors when developing strategies to optimize pain‐related outcomes in SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Children's National Hospital, Washington, District of Columbia, USA.
- Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
- Howard University College of Medicine, Washington, District of Columbia, USA.
- Department of Statistics, George Washington University, Washington, District of Columbia, USA.
ORCID-Profile: Steven J Hardy, Deepika S Darbari
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- Doris Duke Charitable Foundation
- National Institutes of Health
Zitieren
APA
Hardy, S. J., Williams, Z., Berger, C., Griffin, D., Weisman, H., Liang, H., & Darbari, D. S. (2023). Neurocognitive and emotional factors predict pain‐related healthcare utilization in children with sickle cell disease. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30346
Vancouver
Hardy SJ, Williams Z, Berger C, Griffin D, Weisman H, Liang H, et al. Neurocognitive and emotional factors predict pain‐related healthcare utilization in children with sickle cell disease. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30346
BibTeX
@article{Hardy2023,
author = {Hardy, Steven J and Williams, Zaria and Berger, Carly and Griffin, Danielle and Weisman, Hannah and Liang, Hua and Darbari, Deepika S},
title = {Neurocognitive and emotional factors predict pain‐related healthcare utilization in children with sickle cell disease},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30346}
}
EUVIMED